Skip to content

A prospective randomized controlled trial of intense pulsed photodynamics for seborrhea

A prospective randomized controlled trial of intense pulsed photodynamics for seborrhea

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300070978
Enrollment
Unknown
Registered
2023-04-27
Start date
2023-05-01
Completion date
Unknown
Last updated
2023-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Seborrhea

Interventions

Seborrhea group:ALA-IPL

Sponsors

Shanghai Dermatology Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1) Age 18-40 years old, no cognitive dysfunction, male or female; 2) The patient had increased seborrhea on the left and right faces (in line with the 4 criteria of the skin oiliness scale) with enlarged pores (a single surface area greater than 0.3mm2), which met Fitzpatrick III-IV grade; 3) After fully explaining the purpose and content of the clinical trial (including subjects' compliance matters, etc.), voluntarily sign an informed consent form to participate in the clinical trial on the basis of full understanding.

Exclusion criteria

Exclusion criteria: 1) Those who are known to be allergic to experimental drugs or related drugs; 2) Have received relevant treatments that affect seborrhea before enrollment (history of Telse medication in 3 months before enrollment, antibacterial drug use history in 1 month before enrollment, history of facial external drug treatment 2 weeks before enrollment, etc.); 3) Those who took phototoxic or photosensitive drugs (such as sulfonamides, phenothiazines, etc.) within 8 weeks before enrollment; 4) Patients with other diseases on the face that may affect the evaluation of efficacy (dermatitis, acne with inflammatory skin lesions, eczema, skin photosensitivity, porphyria, other photodermal diseases, etc.); 5) Participate in any drug clinical trial (as a subject) within 1 month prior to participating in this trial 6) Serious diseases, including severe heart disease, cerebrovascular disease, uncontrolled diabetes, uncontrolled hypertension, etc.; 7) those with scar constitution; 8) pregnant or lactating women, and subjects of childbearing age (including men) who refused to use appropriate contraception during the study; 9) Subjects with severe physical or psychiatric illness that the investigator believes may affect treatment, assessment, or adherence to the study protocol.

Design outcomes

Primary

MeasureTime frame
Seborrhea;

Secondary

MeasureTime frame
six-item skin oiliness scale ,SOS;

Countries

China

Contacts

Public ContactWang xiuli

Shanghai Dermatology Hospital

xlwang2001@aliyun.com+86 18017336663

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026